[Correspondence] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer
Like Fang Wu and colleagues, we also read with great interest the ADJUVANT study,1 which showed that patients with stage II –IIIA (N1–N2) EGFR-mutant non-small-cell lung carcinoma treated with adjuvant gefitinib had significantly longer disease-free survival and fewer side-effects, than did those treated with vinorelbine plus cisplatin. However, caution should be used when choosing gefitinib as adjuvant treatment bec ause some questions remain unanswered.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Jin-an Ma, Shun Jiang, Chunhong Hu, Yangchun Xie, Tao Hou Tags: Correspondence Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Non-Small Cell Lung Cancer | Study